27 May, 2017
The lowest price the stock reached in the last trading day was $0.02 and compares with the $0.02 52-week low. The day's total volume of 34393947 this morning is in contrast from the three-month daily average of 15280.23K.
Ciena Corporation has a consensus outperform rating from 22 Wall Street analysts, and the number of shares now sold short amount to at least 11.15% of shares outstanding. Analysts have placed a $28.72 price target on Ciena Corporation, suggesting a 23.1% gain from recent close.
Analysts on average have given a price target of $16 to Delcath Systems, Inc.
02/24/2014 - Delcath Systems, Inc. was upgraded to "buy" by analysts at Thomson Reuters/Verus.
Additionally on 5/03/13 Cowen & Co. Over the trailing year, the stock is underperforming the S&P 500 by 114.14, and it's gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. Tightening the gaze, stock performance for the last 5 trading days is -37.30%.
Beta is also an important valuation ratio for analyzing the stock of the company, P has Beta of 0.07 while its industry and Sector's beta remains at 1.53 and 1.33 respectively.
The company surged 1.2% and closed its last trading session at $9.14.
In terms of Buy, Sell or Hold recommendations, Delcath Systems Inc (NASDAQ:DCTH) has analysts' mean recommendation of 2. Analyst rating score as published on FINVIZ are rated on a 1 to 5 scale. The company reported the earnings of $-0.66/Share in the last quarter where the estimated EPS by analysts was $-3.29/share. One of the important differences between earnings-per-share growth rates and net-income growth rates is that the former reflects the dilution that occurs from new stock issuance, the exercise of employee stock options, warrants, convertible securities, and share repurchases. For the most recent quarter, quick ratio was 0.9, current ratio was 1, LT Debt/Equity ratio was 0 and Total Debt/Equity ratio was 0. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 286.21%. Including today's unusual volume, Delcath Systems, Inc.'s stock is performing at -97.38% on the year. The RSI computes momentum as the ratio of higher closes to lower closes: stocks which have had more or stronger positive changes have a higher RSI than stocks which have had more or stronger negative changes. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).